June 23, 2022
Daiichi Sankyo said on June 22 that European regulators have validated its application for Enhertu (trastuzumab deruxtecan), an antibody-drug conjugate (ADC) being codeveloped with AstraZeneca, to treat certain patients with HER2 low breast cancer. The validation opens a review process...read more